[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Barcelonabeta Brain Research Center, Pasqual Maragall Foundation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":147},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,56,104,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100053544","personalized-brain-health-service-and-dementia-prevention-100053544",false,"NCT07698431","Personalized Brain Health Service and Dementia Prevention","Implementation of a Brain Health Service for Personalized Stratification and Prevention of Dementia Risk: The B-HEALTH Project","B-HEALTH","Inclusion Criteria:\n\n* Participants aged 55 to 85 with subjective cognitive complaints and normal screening test performance at the hospital.\n* Participants must have a minimal educational level for a neuropsychological assessment and a minimal digital literacy for the usage of smartphones, computers and Internet.\n\nExclusion Criteria:\n\n* Objective cognitive impairment.\n* Clinically relevant neurological disorders.\n* Major psychiatric disorders.\n* History of drug\u002Falcohol abuse.\n* Unstable medical conditions that could fully explain cognitive complaints, as determined by the investigator.","ALL","55 Years","85 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study evaluates the feasibility of implementing a Brain Health Service (BHS) to assess and reduce dementia risk in individuals with Subjective Cognitive Decline (SCD). A total of 120 participants will be recruited from the Cognitive Disorders Unit at Hospital del Mar and randomly assigned to either a personalized intervention group or a control group receiving general prevention advice.\n\nThe study will assess individual biological and lifestyle-related risk factors for dementia and use validated tools to estimate each participant's risk profile. Participants in the intervention group will be offered a structured dementia risk communication and counseling process, with the option to receive or decline their individual risk estimate.\n\nThe intervention consists of a 6-month multimodal program combining digital and in-person strategies tailored to each participant's risk level. These strategies include personalized recommendations to improve lifestyle factors such as diet, physical activity, sleep, social engagement, and cognitive stimulation.\n\nThe main objectives are to evaluate the feasibility of delivering this type of service, including recruitment, adherence, and retention; to assess the psychological impact of communicating dementia risk; and to examine changes in lifestyle behaviors and cognitive outcomes over time compared with a control group.\n\nThis study addresses the need for early, personalized prevention strategies for individuals with SCD and may inform broader implementation of preventive BHS.",[28],"Subjective Cognitive Decline (SCD)",[30,31,32,33,34,35,36,37,38,39,40,41,42],"Dementia prevention","Alzheimer's disease","Subjective cognitive decline (SCD)","Dementia risk communication","Brain Health Service","Personalized prevention plan","Multimodal intervention","Lifestyle factors","Risk stratification","eHealth","ptau-217","mHealth","non-pharmacological","NOT_YET_RECRUITING","2026-07-07",{"date":46,"type":47},"2026-07-13","ACTUAL",{"date":49,"type":22},"2026-09-01",{"date":51,"type":22},"2028-08-01",{"name":53,"class":54},"Barcelonabeta Brain Research Center, Pasqual Maragall Foundation","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":17,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":69,"conditions":70,"keywords":75,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":55},"100633056","div-ad-barcelona-alzheimers-blood-based-biomakers-for-a-diverse-community-100633056","NCT07521722","DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community","DIV-AD","INCLUSION CRITERIA\n\n* Cognitively Unimpaired individuals aged between 50 and 75 years at the time of signing the informed consent\n* Individuals interested in participating, able to follow study procedures, and who understand that all the tests are carried out in a research context.\n* Explicit desire to participate in the tests and procedures of the study, including: collection of study variables, cognitive and neurologic assessment, blood sampling.\n* Signing the informed consent, agreeing not to receive the research results that will not be of no clinical interest for the participant.\n\nEXCLUSION CRITERIA\n\n* Cognitive decline defined by CDR\\>0.\n* Individuals with cognitive complaints and who have sought for medical help for cognitive impairment at any time in their life\n* Patients with relevant medical illnesses that may significantly interfere with the interpretation of results. This includes auditory and visual perception disorders, active oncological disease under treatment (localized tumors are excluded) and any condition that, in the investigator's opinion, may interfere with the correct performance\u002Finterpretation of the study procedures and\u002For with future permanence in the study.\n* Major psychiatric disorders (according to the DSM-V manual) or diseases that affect cognitive abilities (major depressive episode, bipolar disorder, schizophrenia, etc).\n* Acquired brain damage: history of head trauma with macroscopic parenchymal or non-axial lesion, large-vessel ischemic or hemorrhagic stroke, brain tumours and any other etiologies that can cause acquired brain damage (i.e., chemotherapy or brain radiotherapy).\n* Parkinson's disease, epilepsy under treatment and with frequent seizures (\\> 1\u002Fmonth) in the last year, multiple sclerosis or other neurodegenerative diseases.",true,"50 Years","75 Years",{"count":67,"type":22},250,"OBSERVATIONAL","The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona.\n\nIt will also examine how factors such as age, income, education, and health conditions may affect these levels.\n\nIn addition, the study will identify barriers that may make it difficult to use these blood tests in primary care.\n\nThe final goal is to help ensure that everyone in Barcelona has fair access to early prevention strategies for Alzheimer's disease.",[71,72,73,74],"Alzheimer Disease","Cognitive Dysfunction, Cognitive Disorder","Dementia","Neurodegenerative Disease",[31,76,77,78,79,80,81,82,83,84,85,86,87,30,88,89,90,91,92,93,94,95],"AD","Blood-based biomarkers","Plasma biomarkers","Phosphorylated tau","Amyloid beta","Neurofilament light chain","GFAP","Ethnic diversity","Health disparities","Cognitively unimpaired","Preclinical Alzheimer's disease","Primary care","Cross-cultural cognitive assessment","RUDAS","Dementia knowledge","Dementia stigma","Genetic ancestry","Migrant populations","Health equity","Diversity","2026-04-07",{"date":98,"type":47},"2026-04-13",{"date":100,"type":22},"2026-04-27",{"date":102,"type":22},"2029-01-01",{"name":53,"class":54},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":63,"sex":17,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":55},"100351108","longitudinal-study-for-the-characterization-of-the-phases-of-subjective-perception-of-cognitive-decline-and-mild-cognitive-impairment-of-alzheimers-disease-100351108","NCT03851523","Longitudinal Study for the Characterization of the Phases of Subjective Perception of Cognitive Decline and Mild Cognitive Impairment of Alzheimer's Disease.","AlfaCognition: Longitudinal Study for the Characterization of the Phases of Subjective Perception of Cognitive Decline and Mild Cognitive Impairment of Alzheimer's Disease.","Inclusion Criteria:\n\n1. Men and women between 45 and 74 years at the time of inclusion in the 45-65\u002FFPM2012 study or older than 45 for persons who have not previously participated in 45-65\u002FFPM2012.\n2. Cognitively healthy persons with SCD, as well as people with MCI and mild dementia.\n3. Participation of a relative to perform the subjective memory complaint and clinical interview.\n\nExclusion criteria:\n\n1. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol.\n2. Any significant disorder that could course with cognitive impairment that is not related to AD.\n3. Family history of monogenic AD.","45 Years",{"count":113,"type":22},400,"Alzheimer's disease (AD) is the leading cause of dementia and its prevalence is estimated to exceed 100 million affects by 2050, becoming the main public health problem worldwide. AD is considered a clinicopathological entity characterized by a progressive cognitive impairment with affectation of memory and other cognitive domains, which underlies a neuropathological pattern with extracellular accumulation of β-amyloid protein (Aβ) in the form of neuritic plaques, intracellular deposits of tau protein in the form of neuritic strands and neurofibrillary tangles, neuronal and synaptic loss and glial proliferation. Classically, its definitive diagnosis implied the existence of a clinical phenotype compatible with dementia, together with the neuropathological findings characteristic of the disease. More recently, evidence of clinical and biological changes leading to the dementia phase has led to the development of new diagnostic criteria that divide the course of AD into 3 stages: (1) a pre-clinical phase, which would include persons with positive biomarkers with normal cognitive performance for their age and educational level; (2) a phase of mild cognitive impairment (MCI), characterized by cognitive performance lower than expected by age and educational level; and (3) a dementia phase, once cognitive deficits interfere with the activities of daily living.\n\nRecent research has also shed light into the subdivision of each of the above-mentioned stages in distinct phases. For example, the existence of a subjective perception of cognitive decline or a subtle cognitive decline, have been postulated as phases within the AD preclinical stage.\n\nThe lack of positive results in the different clinical trials performed to date in patients with AD dementia has redirected the focus of therapeutic strategies towards preventing the development of dementia. For this reason, a detailed characterization of the successive clinical and biological changes that lead to the dementia stage is of vital importance in identifying the persons who could benefit from a possible preventive strategy, as well as the optimal moment to carry out the intervention. The the scientific community, is convinced that intervention aiming to prevent the clinical development of AD dementia must be implemented several years before the first symptoms arise.\n\nIn this context, the present project is developed under the hypothesis that subjective cognitive decline (SCD) in individuals with a performance in cognitive tests within normality represents the first symptomatic manifestation of AD. In persons with SCD, the presence of a higher intensity of subjective complaint quantified using a specific subjective complaint questionnaire (SCD-Q) will be associated with lower cognitive performance and a higher rate of conversion to MCI and\u002For dementia. The relationship between the perception of cognitive decline by the subject and his\u002Fher relative will differently vary depending on the stage of the disease: in subjects with progressive cognitive impairment, the subjective perception of cognitive decline will decrease with disease progression whereas the perception of decline will increase with disease progression in their relatives. The degree of perception of cognitive decline throughout the different phases of the disease will be correlated with cognitive and affective patterns as well as with changes in AD biomarkers. These changes will be related to specific brain patterns and abnormal levels of AD biomarkers, which on the other hand will also be present in patients with MCI and mild dementia due to AD.\n\nThe present study has two main objectives that are:\n\n1. To characterize from a cognitive and biomarker (when available) point of view persons with SCD and to study its association with the risk of presenting a progressive cognitive deterioration.\n2. To study the evolution of the subjective perception of cognitive impairment by the participants and their relatives and to analyze its impact in cognitive, affective and functional terms along the clinical-biological continuum of AD.",[71,116,117],"Mild Cognitive Impairment","Subjective Cognitive Decline","RECRUITING","2025-05-27",{"date":121,"type":47},"2025-05-31",{"date":123,"type":47},"2018-02-12",{"date":125,"type":22},"2027-12-31",{"name":53,"class":54},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":63,"sex":17,"minAge":111,"maxAge":65,"enrollmentInfo":134,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":142,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":146,"locationsCount":55},"100261699","brain-characterization-of-amyloid-protein-and-glucose-metabolism-of-alfa-project-participants-100261699","NCT02685969","Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants","Characterization of Cerebral Amyloid Deposition With 18F-Flutemetamol PET and of Glucose Metabolism With 18F-FDG PET in Individuals Enrolled in the ALFA Project.","Inclusion Criteria:\n\n* To sign the study informed consent form approved by the corresponding authorities.\n* Men and women enrolled in the ALFA project (STUDY 45-65 FPM\u002F2012).\n* Participants with a cerebral MRI (magnetic resonance imaging) not suggestive of radiological incidental findings constituting an exclusion criterion.\n* Cognition within psychometrically normal ranges: MMSE (Mini Mental State Examination ≥26 and Semantic Fluency (animals) ≥12.\n* Score of 0 in the CDR scale (Clinical Dementia Rating).\n* Good knowledge of the language and being literate.\n* Female participants should be post-menopausal or present a negative pregnancy test at the moment of PET acquisition.\n\nExclusion Criteria:\n\n* Present cognitive impairment.\n* Presence of clinically relevant psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV-TR) criteria: major depressive disorder, generalized anxiety disorder, schizophrenia or bipolar disorder.\n* Individuals with visual and\u002For hearing impairment.\n* History of encephalitis, ictus or seizures excluding feverish convulsions during childhood.\n* Severe cerebral macrovascular (i.e., multi-stroke) disease or brain tumor (metastasis\u002Fbrain cancer) as verified by magnetic resonance imaging (MRI).\n* Any contraindication to MRI acquisition, (i.e., metal implants) or phobia to performing the scan as determined by the onsite physician.\n* Previous participation in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening and\u002For administration of a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study.",{"count":135,"type":22},570,"Study to understand factors related with the preclinical stages of Alzheimer's Disease and investigate markers that predict its progression.\n\nCross-sectional and single arm study performed on a subgroup of individuals recruited in the ALFA project.\n\nStudy without therapeutic interest for the research participants (440 participants of the ALFA project who have been selected for being cognitively healthy and in their vast majority are direct descendants of patients diagnosed with Alzheimer's Disease).\n\nEach study candidate will be selected from the ALFA project (STUDY 45-65 FPM\u002F2012) according to their clinical characteristics, their compliance to selection criteria and their desire to participate in this study.\n\nAfter signing this study's specific informed consent form, the neuropsychological screening and the brain MRI acquisition will be performed. Once all inclusion criteria are checked, the PET scans with 18F-Flutemetamol and 18F-FDG will be performed",[138],"Alzheimer's Disease",[140,141],"Prevention","Positron Emission Tomography",{"date":121,"type":47},{"date":144,"type":47},"2017-03-01",{"date":125,"type":22},{"name":53,"class":54},""]